EFFICACY AND SAFETY OF NICORANDIL IN ACUTE CORONARY SYNDROME: A META-ANALYSIS

Authors: -

1) Dr. Avichal Dani

Smt. NHLMMC, Ahmedabad, India

Email Address:- asdani98@gmail.com

2) Dr. Shubh Raithatha

Smt. NHLMMC, Ahmedabad, India

Email Address:- raithathashubh@gmail.com

3) Dr. Dev Desai (Corresponding Author)

Smt. NHLMMC, Ahmedabad, India

Email Address:- devhdesai01@gmail.com

Mobile no.:- +91 9173655551

Abstract:-

Background:- Nicorandil acts as a potassium channel opener, however its cardio protective benefit is still uncertain. This meta-analysis was conducted with the objective of evaluating the efficacy of nicorandil in improving cardiovascular outcomes in acute coronary syndrome.

Main Body :- A total of 24 RCTs with 1640 patients in the nicorandil group and 1592 patients in the control group were identified following PRISMA guidelines till November 2019 and were matched for inclusion and exclusion criteria. The following search strings and MESH terms were used: "nicorandil", "ACS", "MACE". Following this, nicorandil was evaluated for its efficacy and safety outcomes. RevMan 5.3 was used for appropriate statistical tests. Fixed and Random Effect Model Test were used and p<0.05 was considered statistically significant.

Results:- Administration of nicorandil was found to be associated with a significant decrease in MACE (RR = 0.686, 95% CI = 0.509-0.925, p=0.013), no-reflow phenomenon (RR =0.395, 95% CI = 0.266-0.588, p<0.001) and worsening of HF (RR =0.441, 95% CI = 0.221-0.882, p=0.021). It was also associated with significant improvement in LVEF (SMD= 0.637, 95% CI= 0.0972 to 1.177, p=0.021) and significant lowering of cTFC (SMD= -0.216, 95% CI= -0.428 to -0.0041, p=0.046)

Conclusions: - Nicorandil does indeed exert a cardio protective effect by improving cardiovascular outcomes. There is a significant decrease in occurrences of MACE and worsening of HF. There is also significant improvement in LVEF.

Keywords: nicorandil, ACS, MACE, cTFC

Background: -

Acute Coronary Syndrome is a medical emergency and if not treated promptly can lead to Death of the patient. If mortality prevented, Myocardial injury, and Myocardial Death is the most important and grave complication of acute coronary syndrome and can precipitate another episode of ACS or can lead to rupture of myocardium and other array of problems.

Nicorandil is a medication that can be used to treat Acute Coronary Syndrome (ACS). Nicorandil is an ATP-sensitive K+ channel opener with antiarrhythmic and cardiac protective properties, including lowering micro-coronary artery flow resistance via relaxing blood vessel smooth muscles and preconditioning. (1) (2) nicotinamide nitrate, and has been shown to decrease infarct size and incidence of arrhythmias after coronary artery ligation and reperfusion in experimental animals.(3) Nicorandil is hypothesised to inhibit calcium input into myocytes and restrict membrane depolarization, hence reducing ATP consumption during ischemia, through its (ATP)-sensitive K+ channel opening action. (4)

Reperfusion of cardiac myocytes after the event has occurred and the patient has been saved is another hallmark of Acute Coronary Syndrome. Reperfusion damage is a major concern that can result in the patient's mortality. As blood is reintroduced to the injured myocardial, locally produced toxins from the damaged or dead myocytes enter the bloodstream, causing harm to the renal and hepatobiliary systems.(5) (6)

Myocardial injury commonly occurs during percutaneous coronary intervention (PCI) and can be easily monitored by measuring myocardial enzymes. (4) it is a lifesaving procedure .(7) it can be seen with reduces the incidence of minor cardiac marker elevation after coronary stenting (4) PCI along with administration of Intravenous Nicorandil seems to be vastly beneficial. (3) (8) (2)

There are paper suggesting that Nicorandil improves the cardiac function and clinical outcome in a case of acute myocardial infarction (3) the same results can be seen with monitoring cardiac enzymes too (9)

Nicorandil is a widely used drug, yet its exact benefits are not known yet. Most importantly, its effect on major advanced cardiac events and left ventricular ejection fraction. It can be seen that as it is used in emergency, it is beneficial to reduce mortality but it is still a matter of question about its benefits on a long term period.

Main Body

Methodology: -

Data source: -

A computerized search was undertaken in PubMed, Cochrane Library, Google Scholar, and the Controlled Trials Meta Register. "Nicorandil", "Acute Coronary Syndrome", "MACE" and "LVEF: were text keywords. Additional studies were found by manually searching the reference lists of pertinent retrieved publications. The only language allowed was English. Human investigations were the only ones that yielded results.

Eligibility Criteria: -

The researchers looked studies that compared Nicorandil vs Control in treatment of acute Coronary Syndrome. Along with Abstracts, letters, comments, editorials, expert opinions, reviews without original data, and case reports, Research papers were also excluded from the analysis if (10) it was impossible to extract the appropriate data from the published articles; [2] there was significant overlap between authors, institutes, or patients in the published literatures; [3] the measured outcomes were not clearly presented in the literatures; [4] the measured outcomes were not clearly presented in the literatures; and [5] articles were written in non-English.

Study Identification: -

All titles and abstracts discovered by the search approach were reviewed by the author. Relevant complete publications were collected for detailed evaluation; two non-author independent reviewers separately assessed them for eligibility criteria.

Data extraction: -

Each qualified manuscript was reviewed by two independent reviewers separately. The number of patients, their age, gender, intervention type, outcome was all collected from each manuscript. Conflicts were addressed by further discussion or consultation with the author and a third party. The modified Jadad score was used to measure the study's quality.

Outcome Measures: -

Outcomes like MACE, no-reflow phenomenon (NRP), LVEF(Left Ventricular Ejection Fraction), cTFC(corrected TIMI Frame Count) and Worsening heart failure were considered.

Statistical analysis: -

All of the information was gathered and placed into software for analysis. To analyze important clinical outcomes, fixed- or random-effects models were used to generate mean difference, standardized mean difference (SMD), odds ratios, and relative risk (RR) with 95 percent confidence intervals (CIs). Statistical heterogeneity was measured with the χ^2 ; P < 0.100 was considered as a representation of significant difference. I² greater than or equal to 50% indicated the presence of heterogeneity.

Results: -

Nicorandil Administration was found to be associated with a significant decrease in MACE (RR = 0.686, 95% CI = 0.509-0.925, p=0.013), which can be supported by (3) (11) (8) (12), whereas (13) (14) strongly suggest otherwise. Nicorandil was also found to be associated with a decrease in worsening of HF (RR =0.441, 95% CI = 0.221-0.882, p=0.021) similar to (8) (15) but (16) is strongly against this concept. It was also associated with significant improvement in LVEF (SMD= 0.637, 95% CI= 0.0972 to 1.177, p=0.021) as seen with (3) but (9) says it worsens LVEF. Nicorandil was associated with decrease in no-reflow phenomenon (RR =0.395, 95% CI = 0.266-0.588, p<0.001) as seen in papers like (5) (17) (11) Nicorandil was found to be responsible for significantly lowering of cTFC (SMD= -0.216, 95% CI= -0.428 to -0.0041, p=0.046) similar to (3) (5)

Discussion: -

Nicorandil is already one of the most important drug while battling acute coronary syndrome and the efficacy of the drug has always saved lives of many patients. The results that can be seen here are only a proof of that. a proof of how good Nicorandil is not only for short term life saving role but at a long term basis too.

As it can be seen in Figure 1, Nicorandil seems to be sufficient enough to not only save the life of the patient but is similarly good in preventing MACE so that patient can lead the life without again combating any major advanced cardiac event. This result can be supported by a number of papers like (18) (5) (12) (11) (8) and many more. We only found 3 papers who says that Nicorandil is actually a reason behind increase amount of MACE as they found it (16) (14) (13)

Figure 2 helps us understand what happens to the already existing heart failure condition when Nicorandil is administered. It is seen with many papers like (8) (3) (15) (14) (11) that Nicorandil should be a drug given to prevent the worsening of heart failure. Only 2 papers contrasted to it (16) (18), but the results of these papers very strongly shows that Nicorandil actually worsens heart failure. Altogether, Nicornadil seems to be helping in preventing the worsening of heart failure.

Overall, a positive impact on LVEF is seen with administration of Nicorandil as per Figure 3. An increase in LVEF is shown by papers like (3) (12) (16) (1) and more. Still, there were some papers like (19) showed that Nicorandil decreases the left Ventricular Ejection Fraction.

No-reflow phenomenon seems to be reducing with administration of Nicorandil as seen in figure 4. Papers like (5)(14)(17)(3) and others strongly suggest the protective role of Nicorandil. Almost all papers found show that Nicorandil decreases the phenomenon.

Figure 5 shows a significant reduction in cTFC, and almost all papers like (3) (14) (5) support this result.

Conclusions: -

With the results it is evident that Nicorandil decreases MACE, NRP while significantly increasing LVEF. It can also be said that it has a protective role in worsening heart failure. All in all, these results suggest that Nicorandil is a highly efficacious drug and should be administered in acute coronary syndrome.

List of abbreviations: -

ACS - Acute Coronary Synderome

PCI - percutaneous coronary intervention

MACE – Major Adverse Cardiac Events

NRP - No-Reflow Phenomenon

LVEF – Left Ventricular Ejection Fraction

cTFC - corrected TIMI Frame Count

References: -

1. Ju Han Kim MHJ, Kyung Ho Yun, Kye Hun Kim, Dong Koo Kang, Seo Na Hong, Sang Yup Lim, Sang Hyun Lee, Yun Sang Lee, Young Joon Hong, Hyung Wook Park, Weon Kim, Young Keun Ahn, Jeong Gwang Cho, Jong Chun Park, Jung Chaee Kang. Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina 2005 [Available from: https://pubmed.ncbi.nlm.nih.gov/15731536/.

2. Yusuke Kawai KH, Hiromi Matsubara, Kazuhiro Dan, Satoshi Akagi, Katsumasa Miyaji, Mitsuru Munemasa, Yoshihisa Fujimoto, Kengo F Kusano, Tohru Ohe. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon 2009 [Available from: <u>https://pubmed.ncbi.nlm.nih.gov/19276198/</u>.

3. Hirotsugu Ono TO, Hiroshi Ishizaka, Hiroyuki Hanada, Takaatsu Kamada, Hiroyuki Onodera, Norio Fujita, Shingo Sasaki, Toshiro Matsunaga, Ken Okumura,. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation 2004 [Available from: https://pubmed.ncbi.nlm.nih.gov/15459610/.

4. Masaaki Murakami KI, Shozo Kusachi, Kazuyoshi Hina, Minoru Hirota, Satoshi Hirohata, Shigeshi Kamikawa, Mutsuko Sangawa, Keizo Yamamoto, Yasushi Shiratori, Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting 2006 [Available from: https://pubmed.ncbi.nlm.nih.gov/16337497/.

5. Satoshi Ota HN, Masaki Takeuchi, Kazuki Nakajima, Tomoaki Nakamura, Shinya Okamoto, Morimichi Setsuda, Katsutoshi Makino, Tetsu Yamakado, Takeshi Nakano, Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART) 2006 [Available from: https://pubmed.ncbi.nlm.nih.gov/16936418/.

6. Yanming Fan QW, Junna Cai, Yongtang Shi, Youliang Zhang, Limei Yao, Xiaogang Wang, Shupo Lin, Yilin Li, Jing Lv, Bin Zhou, Ruijuan Du, Preventive effect of oral nicorandil on contrastinduced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization 2016 [Available from: <u>https://pubmed.ncbi.nlm.nih.gov/26874946/</u>.

7. Toru Miyoshi KE, Kunihisa Kohno,Makoto Nakahama,Masayuki Doi,Mitsuru Munemasa,Masaaki Murakami,Atsushi Takaishi,Yusuke Kawai,Tetsuya Sato,Katsumasa Sato,Takefumi Oka,Natsuki Takahashi,Satoru Sakuragi,Atsushi Mima,Kenki Enko,Shingo Hosogi, . Effect of remote ischemia or nicorandil on myocardial injury following percutaneous coronary intervention in patients with stable coronary artery disease: A randomized controlled trial 2017 [Available from: https://pubmed.ncbi.nlm.nih.gov/28214082/.

8. H Ito YT, K Iwakura, N Nishikawa, T Masuyama, T Kuzuya, M Hori, Y Higashino, K Fujii, T Minamino,. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction 1999 [Available from: https://pubmed.ncbi.nlm.nih.gov/10080465/.

9. Zuoyuan Chen XC, Shan Li, Xuezhen Huo, Xiuxiu Fu, Xiaonan Dongd, Nicorandil improves myocardial function by regulating plasma nitric oxide and endothelin-1 in coronary slow flow 2015

[Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323571/.

10. Satoshi Ota 1 HN, Masaki Takeuchi, Kazuki Nakajima, Tomoaki Nakamura, Shinya Okamoto, Morimichi Setsuda, Katsutoshi Makino, Tetsu Yamakado, Takeshi Nakano, Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). 2006.

11. Qi Qi JN, Tao Chen, Hongshan Yin, Tao Wang, Zhian Jiang, Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction 2018 [Available from: https://pubmed.ncbi.nlm.nih.gov/29726480/.

12. Mizuo Nameki II, Yoshiya Miyazaki, Yoshiaki Sakai, Susumu Namikawa, Nehiro Kuriyama, Nobuyuki Komiyama, Kouichi Tsunoda, Yoshiaki Masuda, Issei Komuro, Comparison between nicorandil and magnesium as an adjunct cardioprotective agent to percutaneous coronary intervention in acute anterior myocardial infarction 2004 [Available from: https://pubmed.ncbi.nlm.nih.gov/14993771/.

13. Young-Guk Ko B-KL, Woong Chol Kang, Jae-Youn Moon, Yun Hyeong Cho, Seong Hun Choi, Myeong-Ki Hong, Yangsoo Jang, Jong-Youn Kim, Pil-Ki Min, Hyuck-Moon Kwon. Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study) 2013 [Available from: https://pubmed.ncbi.nlm.nih.gov/23709432/.

14. Wang ZQ CM, Liu DL, Zheng WX, Cao XZ, Chen H, Huang MF, Luo ZR,. The effect on myocardial perfusion and clinical outcome of intracoronary nicorandil injection prior to percutaneous coronary intervention in ST-segment elevation myocardial infarction 2017 [Available from: https://europepmc.org/article/med/28100342.

15. Hideki Ishii SI, Masaaki Kanashiro, Tetsuya Amano, Kenji Imai, Toyoaki Murohara, Tatsuaki Matsubara, Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction 2005 [Available from:

https://pubmed.ncbi.nlm.nih.gov/16116055/.

16. Akiyoshi Miyazawa YI, Kengo Tanabe, Hiroyoshi Nakajima, Jiro Aoki, Raisuke Iijima, Tomohiro Nakayama, Mitsuharu Hatori, Gaku Nakazawa, Shuzo Tanimoto, Yoshinobu Onuma, Kazuhiro Hara, Intracoronary nicorandil prior to reperfusion in acute myocardial infarction 2006 [Available from: https://pubmed.ncbi.nlm.nih.gov/19755263/.

17. Han Cheol Lee SGA, Jae-Hoon Choi, Tae Kun Lee, Jun Kim, June Hong Kim, Kook Jin Chun, Taek Jong Hong, Yung Woo Shin, Sang-Kwon Lee. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction 2008 [Available from: https://pubmed.ncbi.nlm.nih.gov/18724016/.

18. Chunguang Feng BH, Yi Liu, Lulu Wang , Dongdong Niu, Ming Lou , Cunzhi Lu, Effect of nicorandil administration on myocardial microcirculation during primary percutaneous coronary intervention in patients with acute myocardial infarction 2018 [Available from: https://pubmed.ncbi.nlm.nih.gov/29743901/.

19. Tadasu Akagi KS, Yoshihito Inai, Motoaki Kitagawa, Nobuki Takahashi, Ichiro Hamanaka, Taketoshi Yamazaki, Masato Takebe, Norio Hama, Yuji Hiraoka, Kinzo Ueda, Kiyoshi Nakazawa, Naoki Matsumoto. Continuous administration of nicorandil decreases QT dispersion during the chronic phase of acute myocardial infarction 2006 [Available from: <u>https://pubmed.ncbi.nlm.nih.gov/16823241/</u>.

20. Takayuki Fujiwara TM, Kunihiko Kameda, Naoki Abe, Hirotsugu Ono, Takumi Higuma, Jin Yokoyama, Hiroyuki Hanada, Tomohiro Osanai, Ken Okumura,. Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction 2007 [Available from: <u>https://pubmed.ncbi.nlm.nih.gov/17879021/</u>.

21. Tsuyoshi Isono HK, Yasuo Sutani, Masayuki Motohiro, Satoshi Yamamoto, Shiori Kyoui, Yoshiji Iharada, Kouji Kurimoto, Katsuko Hara, Hakuo Takahashi, Toshiji Iwasaka. Nicorandil

suppressed myocardial injury after percutaneous coronary intervention 2008 [Available from: <u>https://pubmed.ncbi.nlm.nih.gov/17346816/</u>.

 Kiyoyasu Yamada SI, Hideki Ishii, Kazuhiko Yokouchi , Hirokazu Iwata , Ken Sawada , Toyoaki Murohara, Impacts of nicorandil on infarct myocardium in comparison with nitrate: assessed by cardiac magnetic resonance imaging 2016 [Available from: <u>https://pubmed.ncbi.nlm.nih.gov/26531829/</u>.
Takuji Toyama RS, Hiroshi Hoshizaki, Ren Kawaguchi, Naoki Isobe, Hitoshi Adachi, Shigeru Oshima, Koichi Taniguchi, Shu Kasama, Nicorandil administration shows cardioprotective effects in

patients with poor TIMI and collateral flow as well as good flow after AMI 2006 [Available from: <u>https://pubmed.ncbi.nlm.nih.gov/16856571/</u>.

Table 1:- Description of papers													
No.	Author	Type of study	Year of publis hing	Place of resea rch	Sample Size	Me an Ag e	Mal e/Fe male	Durati on of data collecti on	Type of cardiac abnormalit y	Interventio n	Qualit y assess ment		
1	Hirotsugu Ono(3)	Clinical Trial, RCT	2004	Japan	58 (33 Nicorandil, 25 Control)				Acute Myocardial Infarction	Nicorandil, Control	Good		
2	Mizuo Nameki(12)	Clinical Trial, Comparat ive Study, RCT	2004	Japan	40 (Nicorandil, Magnesium, Control)				Acute Myocardial Infarction	Nicorandil, Magnesium, Control	Good		
3	Satoshi Ota(5)	Comparat ive Study, Multicent er Study, RCT	2006	Japan	92 (Nicorandil, Nicorandil, Control)				Acute Myocardial Infarction	Intracoronar y Nicorandil, Intracoronar y and IV Nicorandil, Control	Good		
4	Wang ZQ(14)	RCT	2017	China	158 (53 Nicorandil, 52 Nitroglycerin , 53 Control)			January 2014 to Decem ber 2015	STEMI	Intracoronar y Nicorandil, Intracoronar y Nitroglyceri n, Control	Good		
5	Qi Qi(11)	RCT	2018	China	120 (40 Nicorandil, 40 Sodium Nitroprusside , 40 Control)				Acute STEMI	Intracoronar y Nicorandil, Intracoronar y sodium nitroprusside , Control)	Good		
6	H Ito(8)	Clinical trial,RCT, comparati ve study	1999	Japan	81 (40 Nicorandil, 41 Control)				Acute Myocardial Infarction	Nicorandil, Control	Good		
7	Tadasu Akagi(19)	RCT	2006	Japan	30 (Nicorandil, Nicorandil, Control)				Acute Myocardial Infarction	IV Nicorandil, IV and Oral Nicorandil, Control	Good		
8	Zuoyuan Chen(9)		2015	China	56				Thirty-six patients with CSF in the left anterior descending (LAD) branch and 20 patients with normal coronary	Nicorandil, Control	Good		

								arteries were included.		
9	Fujiwara (20)	RCT	2007	Japan	62 (31 Nicorandil, 31 Control)			Pre treatment for Myocardial Infarction	Nicorandil, Control	Good
11	Tsuyoshi Isono(21)	RCT	2008	Japan	49 (Nicorandil, Control)			patients scheduled to undergo elective PCI	Nicorandil, Control	Good
12	Ju Han Kim(1)	Clinical Trial,RCT	2005	Kore a	200 (100 Nicorandil, 100 Isosorbide Dinitrate)	61 +/- 10	143 M , 57 F	Unstable Angina	Nicorandil, Isosorbide Dinitrate	Good
13	Yamada (22)	RCT	2016	Japan	52			MI patients just before reperfusion	Nicorandil, Control	Good
14	Akiyoshi Miyazawa(16)	Eurointer vention	2006	Japan	70 (35 Nicorandil, 35 control)			STEMI	Nicorandil, Control	Good
15	Takuji Toyama(23)	Controlle d Clinical Trial	2006	Japan	68			AMI	Nicorandil, Control	Good
16	Han Cheon Lee(17)	Clinical Trial, Comparat ive Study	2008	Kore a	73 (37 Nicorandil, 36 Control)			Acute STEMI	Nicorandil, Control	Good
17	Yusuke Kawai(2)	RCT	2009	Japan	408 (206 Nicorandil, 202 Control)			ACS and Non ACS patients	Nicorandil, Control	Good
18	Tory Miyoshi(7)	RCT	2017		391 (Nicorandil, RIPC, Control)			periprocedu ral myocardial injury	Nicorandil, RIPC, Control	Good
19	Masaaki Murakami(4)	RCT	2006	Japan	192 (91 Nicorandil, 101 Control)			Patients undergoing coronary stenting	Nicorandil, Control	Good
20	Young-Guk Ko(13)	Multicent er Study, RCT	2013	Kore a	166 (81 Nicorandil, 85 Control)			patients with renal dysfunction undergoing coronary angiography	Nicorandil, Control	Good
21	Yanming Fan(6)	RCT	2016	China	240 (120 Nicorandil, 120 Control)			patients with an estimated glomerular	Nicorandil, Control	Good

		filtration rate (eGFR)
		of 60 mL/min or
		less, who
		were
		undergoing
		elective
		cardiac
		on



PRISMA Flow Chart

Figures:- .

Comparison 1: - Major Advanced Cardiac Event (MACE)

Figure 1:- MACE

						Weight (%)
Study	Relative risk	95% CI	z	Р	Fixed	Random
Chen2015	0.667	0.121 to 3.666			2.29	2.88
lto1999	0.114	0.006	i33 to 2.048		0.8	1.04
Kawai2009	0.819	0.482 to 1.390			23.77	18.96
Kim2005	0.714	0.259 to 1.973			6.45	7.29
Miyoshi2017	0.894	0.443 to 1.803			13.51	13.05
Murakami2006	0.222	0.0108 to 4.559			0.73	0.95
Ono2004	0.379	0.148 to 0.969			7.55	8.31
Miyazawa2006	1.273	0.674 to 2.403			16.48	15
Lee2008	0.486	0.0949 to 2.493			2.49	3.11
Wang2017	2	0.383 to 10.457			2.43	3.05
Qi2018	0.143	0.0184 to 1.109			1.59	2.03
Ko2013	1.562	0.269 to 9.078			2.15	2.71
Fan2016	0.714	0.233 to 2.188			5.31	6.18
Nameki2004	0.308	0.0775 to 1.221			3.51	4.26
Ota2006	0.386	0.177 to 0.841			10.96	11.17
Total (fixed effects)	0.68	0.528 to 0.874	-3.005	0.003	100	100
Total (random effects)	0.686	0.509 to 0.925	-2.473	0.013	100	100



Comparison 2 :- Worsening Heart Failure (WHF)

Figure 2: - WHF

0							Weigh	nt (%)	
Study	Intervention	Controls Relativ	/e risk	95% CI	z	Ρ	Fixed	Random	
Ito1999	1/40	5/41	0.2050.02	50 to 1.678			10.85	10.85	
Ono2004	3/33	6/25	0.3790.10	5 to 1.369			29.06	29.06	
Myazawa2006	1/35	0/35	30.12	6 to 71.219			4.78	4.78	Π
Wang2017	5/84	11/86	0.4650.16	9 to 1.282			46.7	46.7	h
Qi2018	1/40	2/40	0.50.04	72 to 5.296			8.61	8.61	H
Total (fixed effects)	11/232	24/227	0.4440.22	7 to 0.869	-2.371 0	.018	100	100	F
Total (random effects)	11/232	24/227	0.4410.22	1 to 0.882	-2.316 0	.021	100	100	



Figure 3	: - LV	EF					
Study	Total	SMD	SE	95% CI	t	Р	Fixe
Akagi2006	20	-0.0953	0.429	-0.996 to 0.805			3
Chen2015	52	-0.615	0.28	-1.177 to -	0.0530		9.:
Fujiwara2006	62	2.469	0.335	1.799 to 3.138			6.
Isono2008	49	0.11	0.282	-0.457 to 0.677			9.
Ito1999	81	0.411	0.222	-0.0320 to 0.854			14.4
Kim2005	96	0.795	0.212	0.374 to 1.216			15.
Ono2004	58	2.96	0.379	2.200 to 3.720			4.
Yamada2015	52	0.0427	0.274	-0.508 to 0.593			9.5
Miyazawa2006	57	0.38	0.265	-0.150 to 0.911			10.
Nameki2004	22	0.376	0.416	-0.492 to 1.243			4.:
Toyama2006	68	0.323	0.241	-0.159 to 0.805			12.3
Total (fixed effects)	617	0.539	0.0846	0.373 to 0.705	6.373	<0.001	10
Total (random effects)	617	0.637	0.275	0.0972 to 1.177	2.318	0.021	1

Comparison 3: - Left Ventricular Ejection Fraction



Comparison 4: - No-Reflow Phenomenon (NRP)

Figure 4: - NRP

Figure 4: - NRP							Weight (%)								
Study	Intervention	Controls	Relative	risk	95% CI	z	Ρ	Fixed	Random						
Ito1999	6/40	14/41	(0.4390.18	7 to 1.029			21.73	21.73	_			++		
Ono2004	3/33	7/25	(0.3250.09	31 to 1.132			10.1	10.1	_			-	 	
Ota2006	2/63	5/27	(0.1710.03	54 to 0.830			6.34	6.34	_				_	
Miyazawa2006	5/35	7/35	(0.7140.25	1 to 2.036			14.35	14.35				4		_
Lee2008	2/36	9/36	(0.2220.05	16 to 0.958			7.38	7.38						
Wang2017	3/53	12/53		0.250.074	48 to 0.835			10.82	10.82						
Qi2018	4/40	14/40	(0.2860.10	3 to 0.793			15.11	15.11						
Chen2015	5/26	6/26	(0.8330.29	D to 2.393			14.15	14.15						
Total (fixed effects)	30/326	74/283	(0.3760.25	5 to 0.554	-4.934<0.0	001	100	100						
Total (random effects)	30/326	74/283	(0.3950.26	5 to 0.588	-4.586<0.0	001	100	100						

0.01

0.1

10

1

Comparison 5: - corrected TIMI Frame Count (cTFC)

Figure 5: - cTFC

